GLP-1 receptor agonists may be linked to improved survival outcomes in breast cancer patients. The potential benefits of these drugs are also being explored in patients with other types of cancer, as well as those receiving immunotherapy or having conditions such as obesity or type 2 diabetes. The extent of these benefits and the specific patient populations that may be affected are still being investigated.